MX2021016160A - Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda. - Google Patents

Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda.

Info

Publication number
MX2021016160A
MX2021016160A MX2021016160A MX2021016160A MX2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A
Authority
MX
Mexico
Prior art keywords
terminal fragment
kda
directed against
antibody directed
apoe
Prior art date
Application number
MX2021016160A
Other languages
English (en)
Spanish (es)
Inventor
Charlotte Sahlin
Johanna Fälting
Maria Eriksson
Christer Möller
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of MX2021016160A publication Critical patent/MX2021016160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021016160A 2019-06-28 2020-06-25 Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda. MX2021016160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183405.0A EP3757125A1 (en) 2019-06-28 2019-06-28 Antibody directed against the apoe amino-terminal fragment of 12 kda
PCT/EP2020/067890 WO2020260491A2 (en) 2019-06-28 2020-06-25 New antibody

Publications (1)

Publication Number Publication Date
MX2021016160A true MX2021016160A (es) 2022-04-06

Family

ID=67225987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016160A MX2021016160A (es) 2019-06-28 2020-06-25 Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda.

Country Status (11)

Country Link
US (1) US20220242939A1 (https=)
EP (2) EP3757125A1 (https=)
JP (1) JP2022537736A (https=)
KR (1) KR20220029653A (https=)
CN (1) CN114008074A (https=)
AU (1) AU2020304855A1 (https=)
BR (1) BR112021025956A2 (https=)
CA (1) CA3140999A1 (https=)
IL (1) IL289271A (https=)
MX (1) MX2021016160A (https=)
WO (1) WO2020260491A2 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
JP2009092550A (ja) * 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20170218058A1 (en) * 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Also Published As

Publication number Publication date
AU2020304855A1 (en) 2021-12-23
EP3757125A1 (en) 2020-12-30
BR112021025956A2 (pt) 2022-02-08
IL289271A (en) 2022-02-01
US20220242939A1 (en) 2022-08-04
CN114008074A (zh) 2022-02-01
JP2022537736A (ja) 2022-08-29
CA3140999A1 (en) 2020-12-30
EP3990486A2 (en) 2022-05-04
KR20220029653A (ko) 2022-03-08
WO2020260491A2 (en) 2020-12-30
WO2020260491A3 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
NO20063026L (no) Antistoffer
MY187263A (en) Il-17 reception a antigen binding proteins
PE20071055A1 (es) Anticuerpos anti mn
MX2009010120A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
CY1115927T1 (el) Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2
NZ753324A (en) Bivalent antibodies masked by coiled coils
PH12013500714A1 (en) Anticancer fusion protein
MX2025002472A (es) Combinaciones de anticuerpos anti-c5 y usos de las mismas
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
WO2019081595A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
PH12022551828A1 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
ZA202110285B (en) Antibodies and methods of use
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2025003153A (es) Anticuerpos anti-ccr8
WO2019246176A8 (en) Anti-factor xii/xiia antibodies and uses thereof
MX2023002850A (es) Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap).
EP4269433A3 (en) Tgf-beta-rii binding proteins
MX2021016160A (es) Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda.